Jornalismo CancerThera

2 de April de 2026

Researchers from CEPID CancerThera propose using the Brain-to-Liver Ratio to predict the aggressiveness of bone marrow cancer and measure patient survival based on PET/CT images

In imaging exams that track the body’s energy consumption, the brain is usually the main protagonist, glowing intensely on the

Jornalismo CancerThera

20 de March de 2026

3rd CancerThera Congress consolidates multidisciplinary integration and advances in Cancer Theranostics

The 3rd CancerThera Congress, held from March 11 to 13, 2026, at the School of Medical Sciences of the State

Jornalismo CancerThera

9 de March de 2026

79 abstracts from the 3rd CancerThera Congress are published in a supplement of the journal Hematology, Transfusion and Cell Therapy — Volume 48

The 79 abstracts of scientific works presented during the 3rd CancerThera Congress, held on March 12 and 13, 2026, have

Jornalismo CancerThera

6 de March de 2026

Brazil–Uruguay Alliance: CEPID CancerThera and CUDIM establish partnership to accelerate the development of cancer diagnostics and treatments

The search for more effective and accessible cancer treatments in Latin America gained strategic momentum in February 2026. A delegation

Jornalismo CancerThera

3 de March de 2026

FAPESP Postdoctoral Fellowship at CancerThera – General Biology – Clinical Arm

Field of knowledge: General BiologyFAPESP Process No.: 2021/10265-8Project title: Theranostic Innovation Center in Cancer (CancerThera)Area of activity: Oncology, Molecular Biology,

Jornalismo CancerThera

26 de February de 2026

Early use of the radiopharmaceutical Lutetium-177-PSMA-617 in metastatic prostate cancer improves patients’ daily routine, argue CEPID CancerThera researchers in editorial commentary

Prostate cancer is one of the leading causes of male mortality worldwide, becoming a major clinical challenge when it reaches

Jornalismo CancerThera

23 de February de 2026

Principal Investigator at CancerThera, Elba Etchebehere assumes new international leadership roles and expands the representation of Brazilian Nuclear Medicine

Dr. Elba Etchebehere, nuclear medicine physician, professor at the School of Medical Sciences of the University of Campinas (FCM/Unicamp) and

Jornalismo CancerThera

20 de February de 2026

Fewer side effects, more precision in cancer: the bet on metallopharmaceuticals to overcome the skin barrier is the subject of an article by CEPID CancerThera researchers

Skin cancer remains the most incident cancer in Brazil and worldwide. Although cure rates are high when detected early, conventional

Jornalismo CancerThera

18 de February de 2026

From cancer genetics and metalloradiopharmaceutical research to a Physics degree: how the experience at CEPID CancerThera transformed a student’s trajectory

For many students, choosing a university career is a leap into the unknown. For Maria Eduarda Amaro Santos, however, the

Jornalismo CancerThera

19 de December de 2025

Welcome letter from the president of the 3rd CancerThera Congress

Dear speakers, attendees, and partners, It is with great honor and pleasure that I welcome you to the 3rd CancerThera

Researchers from CEPID CancerThera propose using the Brain-to-Liver Ratio to predict the aggressiveness of bone marrow cancer and measure patient survival based on PET/CT images

3rd CancerThera Congress consolidates multidisciplinary integration and advances in Cancer Theranostics

79 abstracts from the 3rd CancerThera Congress are published in a supplement of the journal Hematology, Transfusion and Cell Therapy — Volume 48

Brazil–Uruguay Alliance: CEPID CancerThera and CUDIM establish partnership to accelerate the development of cancer diagnostics and treatments

FAPESP Postdoctoral Fellowship at CancerThera – General Biology – Clinical Arm

Early use of the radiopharmaceutical Lutetium-177-PSMA-617 in metastatic prostate cancer improves patients’ daily routine, argue CEPID CancerThera researchers in editorial commentary

Principal Investigator at CancerThera, Elba Etchebehere assumes new international leadership roles and expands the representation of Brazilian Nuclear Medicine

Fewer side effects, more precision in cancer: the bet on metallopharmaceuticals to overcome the skin barrier is the subject of an article by CEPID CancerThera researchers

From cancer genetics and metalloradiopharmaceutical research to a Physics degree: how the experience at CEPID CancerThera transformed a student’s trajectory

Welcome letter from the president of the 3rd CancerThera Congress

Contact CancerThera

Menu